Related Experiment Video
Updated: Jun 8, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Prostate neuroendocrine carcinoma successfully treated with etoposide and cisplatin
Masanori Ishizaki1, Masaru Hasumi1, Kazumichi Muramatsu1
1Department of Urology Gunma Prefectural Cancer Center Ota Gunma Japan.
Introduction:
The frequency of neuroendocrine carcinoma of the prostate is low, accounting for approximately 1%-5% of all prostate cancers. Herein, we report the case of a patient who was diagnosed with prostate neuroendocrine carcinoma and successfully treated with etoposide and cisplatin.
Case Presentation:
A 74-year-old man presented to the urology department with the chief complaint of urinary retention. After a thorough examination, he was diagnosed with neuroendocrine carcinoma of the prostate and treated with etoposide and cisplatin, called "EP therapy." The patient remained in remission 1 year later.
Conclusion:
A patient with neuroendocrine carcinoma of the prostate was successfully treated with etoposide and cisplatin, and the patient remained in remission. Prostate neuroendocrine carcinomas are rare and have poor prognoses. Therefore, information regarding treatments that can improve prognosis is needed.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists